KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH) that retains the cytokine-inhibiting anti-inflammatory activity of the parent hormone while being devoid of its melanotropic effects. Unlike full-length α-MSH, KPV does not activate cell-surface melanocortin receptors — instead, it enters cells through a specific receptor-independent uptake mechanism and acts intracellularly.

Once internalized, KPV inhibits NF-κB activation, downregulating the transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8. This intracellular anti-inflammatory mechanism is distinct from receptor-mediated approaches and has been studied particularly in intestinal inflammation models (IBD, colitis, gut barrier dysfunction) and skin inflammation, where KPV demonstrates efficacy via topical and oral routes in addition to parenteral administration.

• Intracellular NF-κB pathway inhibition without melanocortin receptor activation
• Intestinal inflammation, IBD, and colitis preclinical models
• Pro-inflammatory cytokine (TNF-α, IL-1β, IL-6) downregulation studies
• Gut barrier integrity and epithelial healing research
• Skin inflammation, wound healing, and dermatitis models
• Oral and topical bioavailability of anti-inflammatory tripeptides

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Alpha-MSH fragment studied for anti-inflammatory/gut pathways.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.